D3 Bio Gains FDA Clearance for Two Trials
January 19, 2026 | 11:55
The biotechnology company secured regulatory approval to advance two investigational drug studies, including a phase one trial and a combination therapy study, marking progress in its oncology pipeline.
Mobile Version